A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension
brief summary
This is a clinical trial to assess the efficacy and safety of LAM-001 as an add-on therapy for the treatment pulmonary hypertension.
detailed description
This is a Phase 2a, single-arm, open-label, exploratory study assessing the efficacy and safety of LAM-001 as an add-on therapy for the treatment of WHO functional class III subjects with WSPH Group-1 or Group-3 pulmonary hypertension.
Approximately fifteen participants will receive standard of care plus LAM-001 once daily for the first 24 weeks of the study (Core Study).
Participants who complete the first 24 weeks on treatment and appear to have a favorable benefit-risk profile will be eligible to continue receiving LAM-001 for the remainder of the study (Extension Period) up to 12 months.
All participants will complete evaluations during a Follow-Up Period of 4 weeks.
official title
A Phase 2a Single-Arm, Open-Label, Exploratory Study to Assess the Effects of LAM-001 for the Treatment of Pulmonary Hypertension